Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
about
AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progressionAndrogen receptor molecular biology and potential targets in prostate cancerProstate cancer metastasis: roles of recruitment and reprogramming, cell signal network and three-dimensional growth characteristicsAndrogen biosynthesis in castration-resistant prostate cancerDevelopment of Potent and Selective Indomethacin Analogues for the Inhibition of AKR1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase/Prostaglandin F Synthase) in Castrate-Resistant Prostate CancerCrystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancerDifferential effects of genistein on prostate cancer cells depend on mutational status of the androgen receptorNovel Imidazopyridine Derivatives Possess Anti-Tumor Effect on Human Castration-Resistant Prostate Cancer CellsComparing the rules of engagement of androgen and glucocorticoid receptorsEnhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activationEpigenetics meets endocrinology.The role of GATA2 in lethal prostate cancer aggressiveness.IGF2 revs the steroidogenesis engine.Leptin signaling and apoptotic effects in human prostate cancer cell lines.Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer.Inhibitor of differentiation 4 (ID4) inactivation promotes de novo steroidogenesis and castration-resistant prostate cancer.The impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activityBeyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer.Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.Genomic analysis of stress response against arsenic in Caenorhabditis elegans.Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth.Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.Optimisation of an immunohistochemistry method for the determination of androgen receptor expression levels in circulating tumour cells.FOXA1: master of steroid receptor function in cancer.Androgen receptor-driven chromatin looping in prostate cancer.Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer modelsN-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapyHormones and prostate carcinogenesis: Androgens and estrogens.Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancerDevelopment of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.Methoxychalcone inhibitors of androgen receptor translocation and function.Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride.A local paracrine and endocrine network involving TGFβ, Cox-2, ROS, and estrogen receptor β influences reactive stromal cell regulation of prostate cancer cell motility.Integrated analysis identifies a class of androgen-responsive genes regulated by short combinatorial long-range mechanism facilitated by CTCF.Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC).Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?The in vivo role of androgen receptor SUMOylation as revealed by androgen insensitivity syndrome and prostate cancer mutations targeting the proline/glycine residues of synergy control motifs.Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapyAndrogen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival
P2860
Q21203668-B23AE304-5E5D-4A43-B1A0-2C2591E27BC7Q24602861-B028298C-F3BF-4D12-818C-31CA6A1CAEC0Q26773613-656EDF5D-E9F0-4A95-88F5-A55CEB20ECACQ27026044-70292C6C-8D7F-4B32-AADB-396D45AB8D44Q27676555-2E6760AD-EB6E-4EB1-84D1-67A4588403E4Q27678564-6014317E-287A-427F-BF5C-FB157C9BE844Q28534575-CA3307EA-CBDD-4F9A-9166-A043BBDD757FQ28545928-B32CC920-832A-4305-89A0-E438DF156968Q33658855-0CA1EE51-9282-44A7-A763-1F38607E0DF4Q33665345-08302680-5329-4C92-8FA3-9F2820B818D2Q33810295-7D8259AB-6A7E-4D07-BBD2-18A225E9A183Q33848134-F7FF81B8-62D7-4CD6-9728-0153551ED0AFQ33881128-14DE8994-B0B4-4154-9619-1C7FF706209DQ33889654-86C9B218-25EB-40CA-8CD8-DF78D842C8C6Q33932673-4728FA98-BC77-4E1B-B63E-6FE5DCAE0567Q33977414-CAFF0166-5202-4163-9C8C-F9D4036F4B9FQ34189517-4750B84B-56E2-4DF9-B7B9-FB4E7320F083Q34375823-08E9C4C4-A867-49CD-9EE7-8D35E2CF303DQ34478734-7E7DF91F-27C9-44CC-BD88-07536393C47CQ34872369-60EEA349-6BD6-4D63-9D99-62A77A2F93B9Q35048908-0273C683-6069-4DA4-8276-ED747DF5DCA1Q35099127-79FBE489-2861-48AA-BFC8-2785F7825C8BQ35133088-4CBDE3C8-9450-4CBB-AE0E-E1CAB6B3EDE1Q35532767-3BF1BD28-8721-41C6-8E96-B99DBBFA5C94Q35589706-1A3A6EA6-9511-4BA3-A5A5-9A02903EEB64Q35590793-3C64D0C1-F428-4C19-B68A-5123E008E79FQ35611451-6037D5FA-7EB7-42B3-B288-774C71446805Q35687198-2C0E3C88-15FC-4175-B96F-459C8217A311Q35786826-7915E88A-7028-47A2-B6D3-C66AEB9E8467Q35816836-5690FFF4-CCA8-4031-A442-D3E350468008Q35841689-A13CF2C4-F129-482A-BECD-A97EEB49EF54Q35869909-F89657F5-6C91-4E5E-86AD-D9DD3C8F8C16Q35970073-5C9342B2-EAD9-4EDD-95A9-35110AE5BDA1Q36008102-3E7DADB2-55B3-43BE-8138-A6BBD7026570Q36055229-54BB7A60-1CEC-4FE3-A8E1-131A7694EEECQ36113793-9C5FAD80-70A8-4594-9003-77D0DCD630B5Q36225738-FF72BEEA-FA99-4CA4-82C6-6EBFE3026153Q36289592-4EB47A3C-41C9-441F-BAAA-9EB4C34A1CB9Q36398998-EA4B0744-963B-4D87-9216-5C804638D7ECQ36454548-F71DD133-EF65-4FA2-9106-0415570E7875
P2860
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
@ast
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
@en
type
label
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
@ast
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
@en
prefLabel
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
@ast
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
@en
P2860
P1476
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
@en
P2860
P304
P356
10.1016/J.TEM.2010.01.002
P577
2010-02-06T00:00:00Z